A Study of Daratumumab/rHuPH20 Plus Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant MaintenanceTherapy in Patients with Multiple Myeloma Using Minimal Residual Disease to Direct Therapy Duration (S1803)

A Study of Daratumumab/rHuPH20 Plus Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant MaintenanceTherapy in Patients with Multiple Myeloma Using Minimal Residual Disease to Direct Therapy Duration (S1803)

Trial Category:
Hematologic
Phase
III
Contact(s)
Mary Beth Wilwerding, RN
mwilwerding@canceralliance-ne.org
Phone
402-991-8070
Fax
402-991-8850
 
 
Become a NOS Member Today!
Join Now
 

Platinum Corporate Members

Gold Corporate Members